Zeke Capital Advisors’s Safeguard Scientifics, Inc. SFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
$775K Hold
250,000
0.05% 180
2022
Q3
$933K Hold
250,000
0.07% 127
2022
Q2
$933K Hold
250,000
0.06% 136
2022
Q1
$1.3M Buy
250,000
+18,600
+8% +$113K 0.07% 120
2021
Q4
$1.7M Buy
231,400
+27,500
+13% +$215K 0.1% 65
2021
Q3
$1.81M Hold
203,900
0.1% 68
2021
Q2
$1.58M Sell
203,900
-1,068
-0.5% -$7.28K 0.1% 82
2021
Q1
$1.4M Hold
204,968
0.1% 72
2020
Q4
$1.31M Hold
204,968
0.11% 66
2020
Q3
$1.12M Hold
204,968
0.13% 53
2020
Q2
$1.44M Buy
204,968
+1,068
+0.5% +$6.76K 0.28% 43
2020
Q1
$1.13M Hold
203,900
0.32% 44
2019
Q4
$2.24M Hold
203,900
0.19% 102
2019
Q3
$2.31M Hold
203,900
0.2% 91
2019
Q2
$2.46M Hold
203,900
0.23% 87
2019
Q1
$2.21M Buy
+203,900
New +$2.07M 0.21% 93

Other funds holding SFE

Zeke Capital Advisors's SFE Position: Q4 2022 in Review

Zeke Capital Advisors held its Safeguard Scientifics, Inc. (SFE) position steady in Q4 2022 at 250,000 shares worth $775K. The position accounts for 0.05% of the portfolio, ranked #180.

Zeke Capital Advisors first reported a position in SFE in Q1 2019 and has held it in 16 quarters since. The position peaked at $2.46M in Q2 2019. 44 funds tracked by Wall St. Rank hold SFE as of Q4 2022.

  • Zeke Capital Advisors held 250,000 shares of Safeguard Scientifics, Inc. worth $775K as of Q4 2022.
  • Zeke Capital Advisors left its Safeguard Scientifics, Inc. share count unchanged in Q4 2022.
  • Safeguard Scientifics, Inc. made up 0.05% of Zeke Capital Advisors's portfolio in Q4 2022, its #180 holding.
  • Zeke Capital Advisors first reported a position in Safeguard Scientifics, Inc. in Q1 2019 and has held it in 16 quarters since.
  • Zeke Capital Advisors's Safeguard Scientifics, Inc. position peaked at $2.46M in Q2 2019.
  • 44 funds tracked by Wall St. Rank held Safeguard Scientifics, Inc. as of Q4 2022.

Based on Zeke Capital Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.